For Donors and Investors
To this end, FAST is driving translational research and supporting the advancement of therapeutics for animal models to humans living with Angelman syndrome.
The goal is to advance as many promising therapeutic strategies as possible for Angelman syndrome, regardless of the obstacles, to find the best treatment options for our loved ones, for all ages and for all genotypes.
Supporting FAST’s mission can take many different forms.
The GTX Story
Beginning in early 2012, FAST began funding Scott Dindot’s laboratory at Texas A&M University to understand the mechanism by which the UBE3A-antisense transcript (UBE3A-AS) silences the paternal UBE3A allele, why it is only silenced in neurons, and how that process may be circumvented as a potential therapy for Angelman syndrome (AS). Learn More
Regardless of how you join this effort, you will help us continue our work to bring life-changing therapeutics to every individual living with Angelman syndrome. Our goal is to successfully complete this race—and no longer be necessary—by finding a cure.